miR‑452‑5p regulates the responsiveness of intestinal epithelial cells in inflammatory bowel disease through Mcl‑1

Deng,Ming; Hu,Jianglin; Tong,Rui; Guo,Hongming; Li,Xuehui; Liu,Yan

doi:10.3892/etm.2021.10245

miR‑452‑5p regulates the responsiveness of intestinal epithelial cells in inflammatory bowel disease through Mcl‑1

Authors:
- Ming Deng
- Jianglin Hu
- Rui Tong
- Hongming Guo
- Xuehui Li
- Yan Liu
View Affiliations

Affiliations: Department of Anorectal Surgery, People's Hospital of Dongxihu District, Wuhan, Hubei 430040, P.R. China, Department of Gastrointestinal Surgery, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China
Published online on: May 28, 2021 https://doi.org/10.3892/etm.2021.10245
Article Number: 813
Copyright: © Deng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Inflammatory bowel diseases (IBDs) are chronic immune disorders that occur in the intestinal tract. Previous studies have revealed that intestinal epithelial cells (IECs) play critical roles in the development of IBDs, and therapies targeting IECs hold great potential for the treatment of IBDs. However, the roles of microRNAs (miRs) in the regulation of IEC properties and whether they can be used as targets for IEC regulation and IBD treatment are largely unknown. The aim of the present study was to investigate the role of the miR‑452‑5p/Mcl‑1 axis in the regulation of the properties of IECs during the pathology of IBD. A dextran sulfate sodium‑induced mouse model of ulcerative colitis (UC) and an in vitro lipopolysaccharide‑stimulated IEC‑6 cell model were investigated. The results revealed that miR‑452‑5p expression in the IECs of the mice increased significantly upon UC induction, and the knockdown of miR‑452‑5p alleviated the IBD symptoms. Furthermore, the suppression of miR‑452‑5p downregulated the expression of the inflammatory cytokines IL‑6, IL‑8 and TNFα, and upregulated the expression of intestinal barrier‑associated molecules, namely occludin, zona occludens 1 and mucin‑2 in IECs in vitro and in vivo. Notably, the results indicated that miR‑452‑5p modulated the responses of IECs by negatively regulating the expression of Mcl‑1, as the knockdown of Mcl‑1 abrogated the effects of miR‑452‑5p suppression on IECs. The present study suggested that miR‑452‑5p regulated the responsiveness of IECs to influence the development of UC in an Mcl‑1‑dependent manner. These observations provide important information to improve the understanding of IBD pathogenesis and indicate that targeting the miR‑452‑5p‑Mcl‑1 signaling axis in IECs holds potential for IBD treatment.

View Figures

View References

1	Uhlig HH and Powrie F: Translating immunology into therapeutic concepts for inflammatory bowel disease. Annu Rev Immunol. 36:755–781. 2018.PubMed/NCBI View Article : Google Scholar
2	Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L and Colombel JF: Ulcerative colitis. Lancet. 389:1756–1770. 2017.PubMed/NCBI View Article : Google Scholar
3	Torres J, Mehandru S, Colombel JF and Peyrin-Biroulet L: Crohn's disease. Lancet. 389:1741–1755. 2017.PubMed/NCBI View Article : Google Scholar
4	GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 5:17–30. 2020.PubMed/NCBI View Article : Google Scholar
5	Hegyi P, Maleth J, Walters JR, Hofmann AF and Keely SJ: Guts and gall: Bile acids in regulation of intestinal epithelial function in health and disease. Physiol Rev. 98:1983–2023. 2018.PubMed/NCBI View Article : Google Scholar
6	Saavedra PHV, Huang L, Ghazavi F, Kourula S, Vanden Berghe T, Takahashi N, Vandenabeele P and Lamkanfi M: Apoptosis of intestinal epithelial cells restricts Clostridium difficile infection in a model of pseudomembranous colitis. Nat Commun. 9(4846)2018.PubMed/NCBI View Article : Google Scholar
7	VanDussen KL, Stojmirovic A, Li K, Liu TC, Kimes PK, Muegge BD, Simpson KF, Ciorba MA, Perrigoue JG, Friedman JR, et al: Abnormal small intestinal epithelial microvilli in patients with Crohn's disease. Gastroenterology. 155:815–828. 2018.PubMed/NCBI View Article : Google Scholar
8	Geng H, Bu HF, Liu F, Wu L, Pfeifer K, Chou PM, Wang X, Sun J, Lu L, Pandey A, et al: In inflamed intestinal tissues and epithelial cells, interleukin 22 signaling increases expression of H19 long noncoding RNA, which promotes mucosal regeneration. Gastroenterology. 155:144–155. 2018.PubMed/NCBI View Article : Google Scholar
9	Peterson LW and Artis D: Intestinal epithelial cells: Regulators of barrier function and immune homeostasis. Nat Rev Immunol. 14:141–153. 2014.PubMed/NCBI View Article : Google Scholar
10	Turner JR: Intestinal mucosal barrier function in health and disease. Nat Rev Immunol. 9:799–809. 2009.PubMed/NCBI View Article : Google Scholar
11	Pickert G, Neufert C, Leppkes M, Zheng Y, Wittkopf N, Warntjen M, Lehr HA, Hirth S, Weigmann B, Wirtz S, et al: STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J Exp Med. 206:1465–1472. 2009.PubMed/NCBI View Article : Google Scholar
12	Sugimoto K, Ogawa A, Mizoguchi E, Shimomura Y, Andoh A, Bhan AK, Blumberg RS, Xavier RJ and Mizoguchi A: IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest. 118:534–544. 2008.PubMed/NCBI View Article : Google Scholar
13	Wang Y, Mumm JB, Herbst R, Kolbeck R and Wang Y: IL-22 increases permeability of intestinal epithelial tight junctions by enhancing claudin-2 expression. J Immunol. 199:3316–3325. 2017.PubMed/NCBI View Article : Google Scholar
14	Garofalo M and Croce CM: microRNAs: Master regulators as potential therapeutics in cancer. Annu Rev Pharmacol Toxicol. 51:25–43. 2011.PubMed/NCBI View Article : Google Scholar
15	Visone R, Petrocca F and Croce CM: Micro-RNAs in gastrointestinal and liver disease. Gastroenterology. 135:1866–1869. 2008.PubMed/NCBI View Article : Google Scholar
16	Mohammadnia-Afrouzi M, Hosseini AZ, Khalili A, Abediankenari S, Amari A, Aghili B and Nataj HH: Altered microRNA expression and immunosuppressive cytokine production by regulatory T cells of ulcerative colitis patients. Immunol Invest. 45:63–74. 2016.PubMed/NCBI View Article : Google Scholar
17	Wu F, Guo NJ, Tian H, Marohn M, Gearhart S, Bayless TM, Brant SR and Kwon JH: Peripheral blood microRNAs distinguish active ulcerative colitis and Crohn's disease. Inflamm Bowel Dis. 17:241–250. 2011.PubMed/NCBI View Article : Google Scholar
18	Zhao Y, Ma T, Chen W, Chen Y, Li M, Ren L, Chen J, Cao R, Feng Y, Zhang H and Shi R: MicroRNA-124 promotes intestinal inflammation by targeting aryl hydrocarbon receptor in Crohn's disease. J Crohns Colitis. 10:703–712. 2016.PubMed/NCBI View Article : Google Scholar
19	Shi T, Xie Y, Fu Y, Zhou Q, Ma Z, Ma J, Huang Z, Zhang J and Chen J: The signaling axis of microRNA-31/interleukin-25 regulates Th1/Th17-mediated inflammation response in colitis. Mucosal Immunol. 10:983–995. 2017.PubMed/NCBI View Article : Google Scholar
20	Zhai W, Li S, Zhang J, Chen Y, Ma J, Kong W, Gong D, Zheng J, Xue W and Xu Y: Sunitinib-suppressed miR-452-5p facilitates renal cancer cell invasion and metastasis through modulating SMAD4/SMAD7 signals. Mol Cancer. 17(157)2018.PubMed/NCBI View Article : Google Scholar
21	Yamashita A, Inamine T, Suzuki S, Fukuda S, Unoike M, Kawafuchi Y, Machida H, Isomoto H, Nakao K and Tsukamoto K: Genetic variants of SMAD2/3/4/7 are associated with susceptibility to ulcerative colitis in a Japanese genetic background. Immunol Lett. 207:64–72. 2019.PubMed/NCBI View Article : Google Scholar
22	Means AL, Freeman TJ, Zhu J, Woodbury LG, Marincola-Smith P, Wu C, Meyer AR, Weaver CJ, Padmanabhan C, An H, et al: Epithelial Smad4 deletion up-regulates inflammation and promotes inflammation-associated cancer. Cell Mol Gastroenterol Hepatol. 6:257–276. 2018.PubMed/NCBI View Article : Google Scholar
23	Klausen P, Karstensen JG, Coskun M, Săftoiu A, Vilmann P, Cowland JB and Riis LB: SMAD4 protein expression is downregulated in ileal epithelial cells from patients with Crohn's disease with significant inverse correlation to disease activity. Gastroenterol Res Pract. 2018(9307848)2018.PubMed/NCBI View Article : Google Scholar
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
25	Roulis M, Armaka M, Manoloukos M, Apostolaki M and Kollias G: Intestinal epithelial cells as producers but not targets of chronic TNF suffice to cause murine Crohn-like pathology. Proc Natl Acad Sci USA. 108:5396–5401. 2011.PubMed/NCBI View Article : Google Scholar
26	Ito Y, Inoue A, Seers T, Hato Y, Igarashi A, Toyama T, Taganov KD, Boldin MP and Asahara H: Identification of targets of tumor suppressor microRNA-34a using a reporter library system. Proc Natl Acad Sci USA. 114:3927–3932. 2017.PubMed/NCBI View Article : Google Scholar
27	Healy ME, Boege Y, Hodder MC, Böhm F, Malehmir M, Scherr AL, Jetzer J, Chan LK, Parrotta R, Jacobs K, et al: MCL1 is required for maintenance of intestinal homeostasis and prevention of carcinogenesis in mice. Gastroenterology. 159:183–199. 2020.PubMed/NCBI View Article : Google Scholar
28	Ramanan D and Cadwell K: Intrinsic defense mechanisms of the intestinal epithelium. Cell Host Microbe. 19:434–441. 2016.PubMed/NCBI View Article : Google Scholar
29	Odenwald MA and Turner JR: The intestinal epithelial barrier: A therapeutic target? Nat Rev Gastroenterol Hepatol. 14:9–21. 2017.PubMed/NCBI View Article : Google Scholar
30	Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Le Toumelin-Braizat G, Chanrion M, Kelly GL, Gong JN, Moujalled DM, et al: The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature. 538:477–482. 2016.PubMed/NCBI View Article : Google Scholar
31	Nijhuis A, Curciarello R, Mehta S, Feakins R, Bishop CL, Lindsay JO and Silver A: MCL-1 is modulated in Crohn's disease fibrosis by miR-29b via IL-6 and IL-8. Cell Tissue Res. 368:325–335. 2017.PubMed/NCBI View Article : Google Scholar
32	Wang Y and Kong D: MicroRNA-136 promotes lipopolysaccharide-induced ATDC5 cell injury and inflammatory cytokine expression by targeting myeloid cell leukemia 1. J Cell Biochem. 119:9316–9326. 2018.PubMed/NCBI View Article : Google Scholar
33	Zhao C, Wang Y, Jin H and Yu T: Knockdown of microRNA-203 alleviates LPS-induced injury by targeting MCL-1 in C28/I2 chondrocytes. Exp Cell Res. 359:171–178. 2017.PubMed/NCBI View Article : Google Scholar